Phase I study of ethylbis(2,2-dimethyl-1-aziridinyl)phosphinate (AB-163)

@article{Wampler2004PhaseIS,
  title={Phase I study of ethylbis(2,2-dimethyl-1-aziridinyl)phosphinate (AB-163)},
  author={G. Wampler and M. Kuperminc and W. Regelson},
  journal={Cancer Chemotherapy and Pharmacology},
  year={2004},
  volume={4},
  pages={49-52}
}
SummaryEthylbis(2,2-dimethyl-1-aziridinyl)phosphinate (AB-163) was used to treat 27 patients in a phase I trial. The limiting toxicity on a weekly schedule of IV administration involved nausea and vomiting associated with a variety of cholinergic side effects, including possible seizures. A starting dose of 300–400 mg/M2/week is suggested for a Phase II trial. One partial response in a patient with squamous-cell carcinoma of the cervix metastatic to the lungs was seen. 
1 Citations

References

SHOWING 1-10 OF 11 REFERENCES
Radiation potentiating effect of ethyl bis(2,2-dimethyl-1-aziridinyl) phosphinate (AB-163).
Chemical mechanism of the radiation potentiating effects of 2,2-dimethylaziridine-type antitumor agents.
...
1
2
...